Travere Therapeutics, Inc.

TVTX

US89422G1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
7.89 ^USD	-0.63%		-4.01%	-12.24%

07-01	Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000 Growth Index	CI
07-01	Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000E Growth Index	CI

Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about Travere Therapeutics, Inc.

Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000 Growth Index	06-30	CI
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 3000E Growth Index	06-30	CI
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 2000 Growth Index	06-30	CI
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell 2500 Growth Index	06-30	CI
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Transcript : Travere Therapeutics, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM	06-05
Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	05-15
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	05-07	MT
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Transcript : Travere Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M	05-06	MT
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	04-24	MT
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	04-24	MT
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	04-24	CI
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	04-03	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Transcript : Travere Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM	03-12
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	03-11	MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	03-11	CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	02-23	MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	02-23	CI
Travere drug for rare kidney condition recommended for EU approval	02-23	RE
Transcript : Travere Therapeutics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M	02-15	MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI

Chart Travere Therapeutics, Inc.

Duration

Period

More charts

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Travere Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.89 USD

Average target price

14.86 USD

Spread / Average Target

+88.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRAVERE THERAPEUTICS, INC.	-12.24%	601M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.56B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs